Puma Biotechnology, a biopharmaceutical company, is focused on the development of products to increase the supervision of cancer patients. The company’s pipeline includes multiple drug candidates, such as PB272, which is in late-stage development for the adjuvant treatment of breast cancer. The company announced that the National Committee for Quality Assurance (NCCN) has updated its Clinical Practice Guidelines for the treatment of breast cancer.
The first update included the recommendation for the use of NERLYNX (nervex) as an adjuvant treatment for patients with breast cancer that has been positively identified as HER2-positive. The second update included the use of dose escalation as an improved treatment option for patients with breast cancer that has been identified as HER2-positive. Joyce O’Shaughnessy, M.D., a consultant physician at Texas Oncology, noted that the recent update of the NCCN guidelines for treating breast cancer includes the use of neratinib for high-risk patients. Alan Auerbach, the president and CEO of Puma Biotechnology, said that the company’s collaboration with the NCCN has assisted raise the awareness of neratinib among breast cancer patients.